摘要
多发性骨髓瘤(MM)是一种克隆性浆细胞异常增殖性疾病。蛋白酶体抑制剂(PI)的应用使MM的治疗取得了较大进展。其中伊沙佐米是新一代PI,在临床研究中体现出了其在一线治疗、维持治疗和复发难治患者治疗中较好的疗效与安全性,主要体现在延长无进展生存期、较低的外周神经不良反应及长期用药无蓄积毒性等方面。文章综述了伊沙佐米的作用机制、药代动力学、临床研究及不良反应,以期为MM的治疗提供参考。
Multiple myeloma(MM)is a clonal proliferation of abnormal plasma cells.Beginning with the use of proteasome inhibitor(PI),the treatment of MM has been significantly improved.Ixazomib is a new generation of PI,the clinical studies have shown that it has good efficacy and safety in frontline therapy,maintenance therapy and treatment of relapsed/refractory MM patients,mainly reflected in prolonging progression-free survival,low peripheral neurotoxicity and long-term medication without accumulated toxicity.This article reviews the mechanism of action,pharmacokinetics,clinical studies and adverse reactions of ixazomib,in order to provide references for the treatment of MM.
作者
郭志成
吴涛
白海
Guo Zhicheng;Wu Tao;Bai Hai(Department of Hematology,the 940th Hospital of Joint Logistics Support Force of Chinese PLA,Lanzhou 730050,China)
出处
《白血病．淋巴瘤》
CAS
2020年第8期505-508,共4页
Journal of Leukemia & Lymphoma
基金
甘肃省自然科学基金(145RJZA151)。
